Merck, which previously predicted 2024 sales between 20.7 billion ... continues to regain ground from a slump after the end ...

Germany’s Merck KGaA expects annual sales to be at the lower half of its outlook range after third-quarter sales missed ...

As a wave of patent expirations encroaches upon many of the world’s top drugmakers, companies will need to be diligent in ...

According to some analysts, Winrevair could hit sales of $3.9 billion by 2029, so it should help Merck replace lost Keytruda sales. There are other products in the drugmaker's portfolio that ...

Merck's Q3 revenue rises, led by Keytruda's strong 17% YoY growth. Gardasil demand challenges in China impact sales, with ...

Merck KGaA is a healthcare/pharma company that I have been covering and investing in for about 2 years at this point. Q2 2024 ...

Merck KGaA’sMRK-1.94%decrease ... The life-sciences and chemicals group lifted its mid-term outlook for its electronics business, which supplies materials to the chip and display industries ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions.

the potential ethical conflicts of making money from selling healthcare products became increasingly apparent. George Merck addressed this question directly in 1950, proclaiming that: "We try ...

In this article, we are going to take a look at where Merck & Co., Inc. (NYSE ... with a steady demand for products and services due to the biological nature of humans. Stocks like Pfizer Inc ...